- Home
- XFOR vs MVBF Comparison
XFOR vs MVBF Comparison
Compare XFOR & MVBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XFOR | MVBF |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | 143 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.3M | 329.1M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | XFOR | MVBF |
|---|---|---|
| Price | $3.69 | $25.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $28.50 | $27.60 |
| AVG Volume (30 Days) | ★ 543.5K | 32.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.67% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $3,400,000.00 |
| Revenue This Year | $1,263.94 | $1.28 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | ★ N/A | $14.70 |
| Revenue Growth | N/A | ★ 51.92 |
| 52 Week Low | $0.17 | $15.59 |
| 52 Week High | $6.63 | $29.59 |
Technical Indicators
Market Signals| Indicator | XFOR | MVBF |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 33.87 |
| Support Level | $3.52 | $22.50 |
| Resistance Level | $4.09 | $27.15 |
| Average True Range (ATR) | 0.23 | 0.79 |
| MACD | 0.06 | -0.30 |
| Stochastic Oscillator | 83.50 | 20.25 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About MVBF MVB Financial Corp.
MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.